Key Differences in Structure, Mechanisms, Research Applications and Regulation

Research peptides and selective androgen receptor modulators, commonly known as SARMs, are frequently discussed together in the research-compound industry. They may appear in the same laboratory catalogs and are sometimes investigated within overlapping areas of metabolic, endocrine, musculoskeletal and molecular research.

Despite this association, peptides and SARMs are not the same type of compound.

They differ significantly in their molecular structures, biological targets, manufacturing methods, stability, analytical testing requirements and regulatory considerations. Treating the two categories as interchangeable can create confusion, weaken experimental design and lead to inaccurate interpretation of scientific findings.

This guide explains the differences between research peptides and SARMs from a scientific perspective. It also discusses how each category is studied, how compound identity and purity should be verified and why researchers must distinguish preclinical findings from approved medical applications.

Research notice: This article is provided for scientific and educational purposes only. Products discussed by Amino Asylum are intended exclusively for qualified laboratory research and are not intended for human or veterinary consumption.

What Are Research Peptides?

Peptides are short chains of amino acids joined by chemical connections called peptide bonds.

Amino acids contain an amino group, a carboxyl group and a variable side chain. When the carboxyl group of one amino acid joins with the amino group of another, a peptide bond is formed. Repeating this process creates a defined amino-acid sequence.

Peptides are commonly described as chains containing approximately 2 to 50 amino acids, although the distinction between a peptide, polypeptide and protein is not absolute. The sequence, length, charge, folding pattern and chemical modifications of a peptide can all influence its laboratory behavior. arch peptide** is a peptide supplied as a laboratory reagent for controlled scientific investigation. Depending on the study, it may be used to examine:

• Receptor binding
• Cellular signaling
• Enzyme activity
• Protein interactions
• Metabolic pathways
• Immune responses
• Tissue-development mechanisms
• Neurological signaling
• Analytical assay performance
• Experimental biomarker activity

Some peptides reproduce sequences that occur naturally in living organisms. Others are shortened fragments, modified analogues or completely synthetic sequences created to investigate a particular molecular question.

The phrase “research peptide” describes the product’s intended laboratory purpose. It does not automatically indicate that the peptide is an approved medicine, clinically effective treatment or safe for personal administration.

The FDA has established formal development requirements for peptide drug products, including assessments of pharmacokinetics, immunogenicity, drug interactions, safety and effectiveness. A laboratory research peptide has not necessarily completed these processes. Are SARMs?

SARMs are selective androgen receptor modulators.

They are generally synthetic, nonsteroidal small molecules designed to bind to androgen receptors. These receptors normally respond to androgen hormones such as testosterone and dihydrotestosterone.

When an androgen receptor is activated, it can influence gene transcription and biological processes in tissues such as skeletal muscle, bone, reproductive organs, skin and the central nervous system.

The scientific objective behind SARM development was to create compounds that could produce tissue-selective androgen-receptor activity. Researchers hoped this selectivity might preserve certain anabolic effects in muscle and bone while reducing unwanted androgenic activity in other tissues.

However, tissue selectivity is not absolute. The effects of a SARM may depend on the compound, concentration, target tissue, receptor cofactors, metabolic pathway and experimental model.

Several SARMs have been investigated for conditions involving muscle wasting, age-related loss of lean body mass, osteoporosis and cancer-associated cachexia. As of July 2026, no SARM has received FDA approval for human use. des vs SARMs: Quick Comparison

Characteristic	Research peptides	SARMs
Basic structure	Chains of amino acids	Usually nonsteroidal small molecules
Primary targets	Vary widely by peptide	Primarily androgen receptors
Molecular diversity	Extremely broad	More narrowly associated with androgen-receptor modulation
Production	Frequently produced through peptide synthesis or biotechnology	Produced through conventional small-molecule chemical synthesis
Stability	Often sensitive to heat, moisture, oxidation and enzymes	Frequently more chemically stable than peptides, although stability varies
Common analytical methods	HPLC, mass spectrometry, amino-acid analysis and sometimes NMR	HPLC or UPLC, LC-MS, NMR and quantitative assay methods
Research applications	Metabolic, neurological, immune, tissue, receptor and analytical research	Androgen-receptor, muscle, bone and endocrine research
FDA status	Some specific peptide medicines are approved; many research peptides are not	No SARM is currently FDA approved
Anti-doping status	Depends on the specific peptide	SARMs are prohibited in sport
Interchangeable categories?	No	No

The Main Structural Difference

The most fundamental difference between peptides and SARMs is their chemical composition.

Peptide structure

Peptides consist of amino-acid residues arranged in a defined sequence.

Even a small change in that sequence can alter:

• Receptor affinity
• Biological activity
• Solubility
• Charge
• Resistance to enzymatic degradation
• Three-dimensional conformation
• Aggregation potential
• Experimental stability

Peptides may also contain disulfide bonds, terminal modifications, lipid groups, fluorescent labels, nonstandard amino acids or other structural additions.

Because peptides resemble naturally occurring biological signaling molecules, they can interact with receptors, enzymes, transport proteins and cellular membranes in highly specific ways.

SARM structure

Most SARMs are synthetic small molecules rather than amino-acid chains.

Different SARMs can have substantially different chemical structures, but they are grouped together because of their intended ability to interact selectively with the androgen receptor.

Their smaller nonpeptide structures may offer different laboratory characteristics, including greater resistance to enzymatic breakdown and different solubility or membrane-permeability profiles.

A peptide and a SARM might both be examined in a muscle-related research model, but this does not mean they share the same structure or mechanism.

How Research Peptides Work

There is no single mechanism that applies to every peptide.

Peptides can interact with many different molecular targets. Some bind to receptors located on cell surfaces. Others influence enzymes, ion channels, intracellular proteins or extracellular structural components.

When a signaling peptide binds to a cell-surface receptor, it may initiate a chain of intracellular events. Depending on the receptor, this can affect:

• Cyclic adenosine monophosphate signaling
• Calcium movement
• Protein kinase activation
• Gene expression
• Cellular growth
• Energy metabolism
• Cytokine production
• Cell migration
• Protein synthesis
• Apoptosis

Other peptides may act as enzyme substrates, competitive inhibitors, molecular probes, antibody-recognition sequences or analytical standards.

This diversity means that two research peptides can have almost nothing in common beyond the fact that both are composed of amino acids.

Researchers must therefore evaluate each peptide individually. Its sequence, target, mechanism, stability and evidence base cannot be inferred from the broader peptide category.

How SARMs Work

SARMs primarily act through the androgen receptor, which belongs to the nuclear-receptor family.

After a SARM enters a cell and binds to the androgen receptor, the receptor-compound complex can interact with regulatory proteins and DNA. This may change the expression of androgen-responsive genes.

The resulting response can vary between tissues because different cells contain different concentrations of receptors, enzymes, transcription factors and receptor-regulating proteins.

This variation is the foundation of the proposed tissue selectivity of SARMs.

In laboratory studies, SARM research has frequently focused on:

• Androgen-receptor activation
• Skeletal-muscle signaling
• Bone metabolism
• Protein synthesis
• Lean-tissue preservation
• Receptor selectivity
• Hormonal feedback
• Liver metabolism
• Gene transcription
• Pharmacokinetics

Although several SARMs have increased lean body mass in experimental or clinical studies, increases in lean mass have not consistently produced meaningful improvements in physical function, mobility, quality of life or clinical outcomes. Safety concerns have also limited regulatory progress. very Compound Marketed Beside SARMs Is a SARM

One of the most common sources of confusion is the use of “SARMs” as a broad marketplace category.

Online stores and discussion forums sometimes place multiple research compounds under the SARM label even when those compounds do not act through the androgen receptor.

Two common examples are GW-501516 and MK-677.

GW-501516

GW-501516, often called Cardarine, is not a selective androgen receptor modulator.

It is a peroxisome proliferator-activated receptor delta, or PPARδ, agonist. Its primary mechanism involves a nuclear receptor associated with lipid metabolism, energy regulation and fatty-acid oxidation rather than the androgen receptor. 77

MK-677, also known as ibutamoren, is not a SARM either.

It acts as a growth-hormone secretagogue receptor agonist and interacts with the ghrelin receptor pathway. Its mechanism is therefore distinct from androgen-receptor modulation. tinction matters scientifically.

Compounds grouped together for website navigation, inventory organization or general discussion should not automatically be assumed to belong to the same pharmacological class.

Researchers should classify a compound according to its verified molecular target, not according to the category in which it commonly appears online.

Research Applications of Peptides

The diversity of peptide structures supports an equally diverse range of research applications.

Receptor-signaling research

Peptides are frequently used to investigate how receptors recognize biological signals and transmit information into cells.

Researchers may evaluate receptor affinity, activation, inhibition, internalization and downstream signaling.

Metabolic research

Certain peptides are studied in models involving:

• Glucose signaling
• Energy expenditure
• Lipid metabolism
• Mitochondrial function
• Appetite-related pathways
• Insulin signaling
• Cellular nutrient sensing

Findings from isolated cells or animal models must not be presented as proof of human therapeutic effectiveness.

Tissue and regenerative biology

Some peptides are examined in studies of:

• Fibroblast activity
• Extracellular matrix organization
• Collagen-associated pathways
• Angiogenesis
• Cell migration
• Tendon models
• Muscle-cell signaling
• Wound-related laboratory models

These areas include compounds such as BPC-157 and TB-500, whose available evidence is predominantly preclinical. Researchers should distinguish mechanistic observations from clinically confirmed outcomes.

Neurological research

Neuropeptides and peptide analogues may be investigated in models involving neurotransmission, learning, memory, stress responses, neuroinflammation and neuronal development.

Immune and inflammatory research

Peptides can function as immune mediators, antimicrobial molecules or regulators of inflammatory signaling.

They may be studied for interactions with cytokines, immune cells, microbial membranes and innate defense mechanisms.

Analytical research

Synthetic peptides are also valuable as:

• Mass-spectrometry standards
• Immunoassay components
• Antibody-validation sequences
• Proteomic reference materials
• Calibration standards
• Biomarker controls

Research Applications of SARMs

Compared with peptides, the research applications of SARMs are more narrowly connected to androgen-receptor biology.

Skeletal-muscle research

SARMs have been investigated in laboratory and clinical-development programs involving muscle wasting, loss of lean mass and age-related changes in skeletal tissue.

Bone research

Because androgen signaling influences bone formation and maintenance, SARMs have been studied in osteoporosis and bone-density models.

Cancer-cachexia research

Some development programs have examined whether androgen-receptor modulation could reduce muscle loss associated with cancer and other chronic diseases.

Endocrine research

SARMs can be used to investigate:

• Receptor selectivity
• Hypothalamic-pituitary-gonadal feedback
• Hormone-responsive gene expression
• Tissue-specific androgen activity
• Metabolic conversion
• Liver-associated biochemical changes

These applications remain areas of investigation rather than proof that SARMs are safe or approved treatments.

Peptide Manufacturing

Many synthetic peptides are manufactured using solid-phase peptide synthesis.

During this process, amino acids are added one at a time to a growing chain attached to a solid resin. Each synthesis cycle generally includes deprotection, coupling and washing stages.

After the complete sequence has been assembled, the peptide is:

1. Removed from the resin
2. Deprotected
3. Purified
4. Analytically characterized
5. Frequently lyophilized

Purification is commonly performed through preparative high-performance liquid chromatography.

Peptide synthesis can produce deletion sequences, truncated chains, oxidized material, incompletely deprotected products and other peptide-related impurities. The difficulty may increase as sequences become longer or structurally complex.

This makes identity confirmation and impurity characterization essential.

SARM Manufacturing

SARMs are usually manufactured using conventional small-molecule organic chemistry.

The process may involve multiple reaction steps, solvents, catalysts, purification stages and crystallization procedures.

Potential quality problems can include:

• Incorrect molecular identity
• Unreacted starting materials
• Reaction by-products
• Isomers
• Residual solvents
• Degradation products
• Incorrect concentration
• Cross-contamination
• Undeclared active compounds

The final product must be analyzed to determine whether it contains the claimed substance and whether the measured quantity agrees with the label.

Testing Research Peptides

A peptide’s appearance cannot establish its identity or quality.

A complete analytical evaluation may include several complementary methods.

High-performance liquid chromatography

HPLC separates components within a sample and estimates chromatographic purity.

A result such as 98% purity generally means that the primary peak represents approximately 98% of the detected chromatographic peak area under the conditions used.

It does not necessarily mean that 98% of the entire vial weight is active peptide.

Mass spectrometry

Mass spectrometry measures molecular mass and helps confirm whether the material is consistent with the expected peptide.

Purity and identity are separate measurements. A high HPLC result cannot prove that the principal peak is the correct peptide without an identity test.

Peptide-content analysis

A lyophilized peptide preparation may contain water, counter-ions, salts or excipients. Net peptide content may therefore differ from total vial weight.

This distinction is especially important when preparing quantitative reference standards.

Additional testing

Depending on the research application, testing may also examine:

• Water content
• Counter-ion content
• Residual solvents
• Amino-acid composition
• Aggregation
• Endotoxin
• Bioburden
• Sterility
• pH after preparation

Modern characterization of synthetic peptide standards may combine chromatography, mass spectrometry, nuclear magnetic resonance and other analytical techniques. ng SARMs

SARMs also require both qualitative and quantitative analysis.

Common methods include:

HPLC or UPLC

Chromatography can separate the target compound from related impurities and degradation products.

Liquid chromatography-mass spectrometry

LC-MS combines chromatographic separation with molecular-mass analysis. It can support identity testing and impurity detection.

Nuclear magnetic resonance

NMR can provide detailed structural information and help distinguish compounds with similar molecular masses.

Quantitative assay

Researchers need to know not only whether the claimed compound is present, but also how much is present.

A product may contain the correct molecule at a concentration that differs substantially from its label.

This is a documented concern in the online SARM market. In one investigation of 44 products marketed as SARMs, only 52% contained a SARM. Twenty-five percent contained substances not listed on the label, 9% contained no active substance and 59% contained quantities that differed from the label. the study examined a limited number of products purchased in 2016, it demonstrates why independent testing and batch-specific documentation are essential.

How to Read a Certificate of Analysis

A Certificate of Analysis, or COA, should correspond to the exact batch being supplied.

A useful COA should contain:

• Product name
• Chemical or amino-acid identity
• Batch or lot number
• Date of analysis
• Expected molecular weight
• Observed molecular mass
• Purity result
• Quantitative assay where applicable
• Analytical methods
• Chromatograms or spectra
• Testing-laboratory information
• Authorized review
• Storage recommendations

Researchers should verify that the lot number on the product matches the lot number on the COA.

A generic document reused across multiple batches provides limited assurance. Analytical results can change between manufacturing runs, even when the product name remains the same.

Researchers can consult the Amino Asylum guide on how to read a Certificate of Analysis for research compounds for a more detailed breakdown of chromatograms, spectra and batch verification.

Stability and Storage Differences

Peptides and SARMs often require different storage considerations.

Peptide stability

Peptides can be affected by:

• Heat
• Moisture
• Light
• Oxygen
• Repeated temperature changes
• Unsuitable pH
• Enzymatic degradation
• Repeated freeze-thaw cycles

Potential degradation pathways include oxidation, hydrolysis, deamidation, aggregation and peptide-bond cleavage.

Lyophilization generally improves stability by removing much of the water from the preparation. However, the ideal storage condition still depends on the individual sequence.

Researchers should consult compound-specific documentation and the Amino Asylum Research Peptide Storage and Handling Guide rather than assuming all peptides are stable under identical conditions.

SARM stability

Many SARMs are comparatively stable small molecules, but they are not immune to degradation.

Light exposure, heat, oxidation, solvent incompatibility and prolonged storage can still alter a SARM preparation.

Researchers should document:

• Storage temperature
• Container type
• Light exposure
• Solvent composition
• Preparation date
• Freeze-thaw history
• Observed precipitation
• Batch and expiration information

Visible clarity does not prove chemical stability. A solution can appear unchanged while degradation has already occurred.

Preclinical Evidence Is Not Clinical Proof

Scientific evidence must be interpreted according to the model in which it was generated.

In-vitro studies

In-vitro research may use isolated receptors, enzymes, cells or tissues.

These experiments help explain molecular mechanisms but cannot reproduce the complexity of an entire organism.

Animal studies

Animal models provide information about how a compound behaves within a living biological system.

However, species differences in receptors, enzymes, metabolism, dosing, tissue distribution and immune responses can limit direct translation to humans.

Human clinical studies

Human studies can provide stronger evidence, but their quality depends on:

• Sample size
• Study design
• Control groups
• Randomization
• Blinding
• Duration
• Participant characteristics
• Outcome selection
• Adverse-event monitoring

An increase in a laboratory marker or lean-body-mass measurement does not automatically establish improved health, function or long-term safety.

Neither peptides nor SARMs should be discussed as a single evidence category. Each compound requires an individual review of its mechanism, research stage and available data.

Are Peptides Safer Than SARMs?

It is scientifically inaccurate to claim that all peptides are safer than all SARMs or that all SARMs are more dangerous than all peptides.

“Peptide” describes an enormous chemical category. Some peptide medicines have been extensively studied and approved. Other experimental peptides have little or no reliable human safety information.

The FDA has identified significant safety concerns or major evidence gaps involving several bulk peptide substances, including risks related to immunogenicity, aggregation, impurities and inadequate human-exposure data. e also not FDA approved. The FDA has associated their unauthorized personal use with reports of liver injury, cardiovascular events, sexual dysfunction, infertility and other serious health problems. ect question is not whether peptides or SARMs are universally safer.

Researchers should instead ask:

• What exact compound is being studied?
• What evidence is available?
• Has the material been correctly identified?
• What impurities may be present?
• What biological model is being used?
• Are the methods ethically and legally authorized?
• Are the conclusions limited to what the data actually demonstrate?

Regulatory Status in the United States

The regulatory status of a substance depends on its identity, intended use, marketing claims and whether an approved application exists.

Research peptides

Some specific peptide drug products have received FDA approval after completing formal development and regulatory review.

However, this does not mean that every peptide is approved.

When an unapproved peptide is marketed with claims that it can diagnose, treat, cure, mitigate or prevent disease, the FDA may classify it as an unapproved new drug.

A “research use only” disclaimer does not automatically prevent enforcement when the surrounding product descriptions, instructions, testimonials or marketing demonstrate an intended human use. FDA warning letters issued in 2026 continued to apply this principle to peptide sellers. s

As of July 2026, SARMs are not FDA-approved drugs and cannot legally be marketed in the United States as dietary supplements or approved medicines.

The FDA has repeatedly issued warning letters and pursued enforcement against companies marketing SARMs for bodybuilding, physical performance or personal use. enforcement practices can differ by jurisdiction. Laboratories should obtain appropriate legal and institutional guidance before acquiring, transferring or studying regulated research compounds.

Peptides, SARMs and Anti-Doping Rules

Researchers working with athletes, sports laboratories or performance-testing programs must consider anti-doping regulations.

The World Anti-Doping Agency’s 2026 Prohibited List places SARMs within section S1.2, covering other anabolic agents. Listed examples include andarine, enobosarm or ostarine, LGD-4033, RAD140 and S-23. They are prohibited at all times for athletes governed by the World Anti-Doping Code. are more complex.

Peptides as a broad chemical category are not automatically prohibited. However, specific peptide hormones, growth factors, related substances, mimetics and growth-hormone secretagogues may be prohibited under other sections of the WADA list.

For example, ibutamoren is classified as a growth-hormone secretagogue rather than a SARM and is prohibited under the relevant hormone-related category. ers should consult the current prohibited list rather than relying on product categories or informal online descriptions.

How Researchers Should Evaluate a Supplier

The reliability of an experiment depends partly on the quality of the material used.

Before purchasing research peptides or SARMs, laboratories should assess several factors.

Batch-specific documentation

Every batch should have traceable analytical documentation.

Identity testing

A purity percentage alone is not sufficient. The supplier should provide an appropriate identity-confirmation method.

Quantitative accuracy

For liquid compounds, the measured concentration should agree with the labeled concentration.

For lyophilized peptides, researchers may need peptide-content information in addition to chromatographic purity.

Independent testing

Third-party testing can provide greater confidence when the laboratory is clearly identified and the report is independently verifiable.

Transparent limitations

Responsible suppliers should avoid unsupported medical claims and clearly state that unapproved research products are not intended for personal use.

Proper storage and shipping

The supplier should provide storage recommendations and use packaging appropriate for the stability requirements of the material.

Accessible policies

Shipping, testing, returns, privacy and compliance information should be available before an order is placed.

Amino Asylum publishes batch-specific Certificates of Analysis and supplies its research catalog exclusively for laboratory investigation. The company’s Research Library is intended to help researchers understand compound mechanisms, analytical documentation, storage and regulatory limitations rather than rely on marketing claims alone.

Frequently Asked Questions

Are peptides and SARMs the same?

No. Peptides are amino-acid chains, while SARMs are generally synthetic small molecules that interact with androgen receptors.

Do peptides and SARMs produce the same effects?

No. Peptide mechanisms vary widely. SARMs primarily affect androgen-receptor signaling. Any overlap in a research outcome does not mean the compounds work through the same pathway.

Are all research peptides hormones?

No. Some peptides function as hormones, but others are neurotransmitters, enzyme substrates, immune mediators, structural fragments, antimicrobial molecules or analytical standards.

Are all compounds sold in SARM categories true SARMs?

No. GW-501516 is a PPARδ agonist, while MK-677 is a ghrelin-receptor agonist and growth-hormone secretagogue. Neither is a true selective androgen receptor modulator.

Are SARMs approved medicines?

No SARM is currently approved by the FDA for human use.

Are any peptides approved medicines?

Yes. Some specific peptide drug products have been approved after regulatory review. This does not make unapproved research peptides equivalent to approved medicines.

What is the best way to confirm peptide identity?

Mass spectrometry is commonly used to confirm molecular mass. Depending on the application, researchers may also require amino-acid analysis, NMR or other sequence-specific characterization.

Is HPLC purity enough?

No. HPLC can estimate chromatographic purity but does not independently confirm that the main peak is the correct compound.

Why is quantitative testing important for SARMs?

A product may contain the named compound but at a concentration significantly different from its label. Accurate quantitative assays are necessary for reproducible research.

Are SARMs prohibited in sport?

Yes. SARMs are included in the WADA Prohibited List and are prohibited at all times for athletes subject to the World Anti-Doping Code.

Are all peptides prohibited in sport?

No. Prohibition depends on the specific compound. Certain peptide hormones, growth factors, mimetics and related substances are prohibited, while peptides as a general chemical class are not automatically banned.

Can preclinical research establish human safety?

No. Cell and animal studies can support scientific hypotheses, but controlled human studies are required to establish human safety and effectiveness.

Final Thoughts

The comparison between research peptides and SARMs begins with a simple scientific fact: they are fundamentally different compound classes.

Peptides are amino-acid sequences capable of interacting with a vast range of biological targets. SARMs are generally synthetic small molecules developed to influence androgen-receptor signaling selectively.

They differ in:

• Molecular structure
• Biological targets
• Research applications
• Manufacturing
• Stability
• Quality-control requirements
• Available evidence
• Regulatory treatment

Researchers should not select or evaluate these materials according to online popularity, product-category labels or unverified claims.

Every compound should be assessed individually through its molecular identity, mechanism, analytical documentation, evidence base and intended experimental application.

The most important questions remain the same for both research peptides and SARMs:

1. Is the compound correctly identified?
2. Does the batch contain the quantity stated on the label?
3. Has purity been measured using an appropriate method?
4. Are the limitations of the available evidence clearly understood?
5. Is the proposed work authorized, ethical and compliant?

Accurate classification and transparent testing are not optional details. They are the foundation of reproducible research.

References

1. Forbes J. Biochemistry, Peptide. StatPearls, National Center for Biotechnology Information.
2. Hoofnagle JH. Selective Androgen Receptor Modulators. LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases. Updated September 2025.
3. U.S. Food and Drug Administration. FDA Warns of Use of Selective Androgen Receptor Modulators Among Teens and Young Adults.
4. U.S. Food and Drug Administration. Clinical Pharmacology Considerations for Peptide Drug Products.
5. World Anti-Doping Agency. 2026 List of Prohibited Substances and Methods.
6. Van Wagoner RM, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA.
7. McCarthy D, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics.
8. Lian Z, et al. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography and Mass Spectrometry.
9. Dimopoulos N, et al. Research on GW-501516 as a Selective PPARδ Agonist.
10. Bright GM, et al. Research on Ibutamoren as a Growth-Hormone Secretagogue Receptor Agonist.

Disclaimer: This article is intended solely for scientific and educational purposes. Amino Asylum research compounds are supplied exclusively for qualified laboratory investigation. They are not intended for human or veterinary consumption, personal administration, diagnosis, treatment, cure or prevention of disease.